超声脉冲电导联合耳穴埋豆对肝癌动脉灌注化疗患者生活质量的效果评价

傅凌雪; 余慧茜; 王奕英; 何莹; 陈水兵; 姚红响

doi:10.16766/j.cnki.issn.1674-4152.002624

超声脉冲电导联合耳穴埋豆对肝癌动脉灌注化疗患者生活质量的效果评价

doi: 10.16766/j.cnki.issn.1674-4152.002624

温州医科大学附属第二医院介入治疗综合外科，浙江温州 325000

基金项目:

浙江省医药卫生科技计划项目 2019PY048

温州市科技局项目 Y20210541

详细信息

通讯作者:
余慧茜, E-mail: fjf225588@126.com

中图分类号: R375.7 R245.9
计量
- 文章访问数: 206
- HTML全文浏览量: 81
- PDF下载量: 0
- 被引次数: 0
出版历程
- 收稿日期: 2021-10-21
- 网络出版日期: 2022-11-29

Effects of ultrasonic pulsed conductance therapy combined with auricular point pressing with beans on the quality of life of patients with liver cancer undergoing arterial perfusion chemotherapy

Department of Interventional Surgery, the Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325000, China

摘要

摘要: 目的探讨超声脉冲电导联合耳穴埋豆对肝癌动脉灌注化疗患者生活质量的临床效果。方法回顾性分析2020年9月—2021年2月在温州医科大学附属第二医院治疗的92例肝癌动脉灌注化疗患者的诊疗资料，根据治疗方法不同分为对照组(42例，一般常规治疗)和观察组(50例，超声脉冲电导联合耳穴埋豆)。干预2个月后，比较2组患者干预前后营养状况[总蛋白(TP)、ALB、血红蛋白(HGB)]，肝功能(ALT、AST)，并采用Karnofsky功能状态评分(KPS)量表和生活质量评分量表(QOL)评价患者生活质量。结果观察组干预后血清TP[(76.53±9.79)g/L]、ALB[(49.08±5.56)g/L]、HGB[(126.56±18.17)g/L]及KPS[(81.91±8.07)分]、QOL[(47.84±6.75)分]评分明显高于对照组[(70.10±9.32)g/L、(45.79±5.70)g/L、(118.20±18.09)g/L、(75.46±8.32)分、(40.30±6.96)分，t=3.207、2.795、2.203、3.765、5.262，均P＜0.05]。干预后，观察组ALT[(42.68±9.71)U/L]、AST[(43.29±9.48)U/L]明显低于对照组[(47.15±9.20)U/L、(49.03±9.42)U/L，t=2.253、2.901，均P＜0.05]。结论超声脉冲电导联合耳穴埋豆可明显改善肝癌动脉灌注化疗患者营养状况、肝功能，提升患者生活质量。
- 肝癌 /
- 超声脉冲电导 /
- 耳穴埋豆 /
- 生活质量 /
- 肝功能
Abstract: Objective To investigate the intervention effect of ultrasonic pulsed conductance therapy combined with auricular point pressing with beans on the quality of life of patients with liver cancer undergoing arterial perfusion chemotherapy. Methods The clinical data of 92 patients with liver cancer undergoing arterial infusion chemotherapy in the Second Affiliated Hospital of Wenzhou Medical University from September 2020 to February 2021 were retrospectively selected. According to the different treatment methods, they were divided into the control group (42 cases, general routine treatment) and experimental group (50 cases, ultrasonic pulse conductance therapy combined with auricular point pressing with beans). At 2 months after the intervention, the nutritional status [total protein (TP), albumin (ALB) and haemoglobin (HGB)], liver function [alanine aminotransferase (ALT) and glutamic-oxaloacetic aminotransferase (AST)] before and after the intervention were analysed and compared between the two groups, and Karnofsky functional status scale (KPS) and quality of life (QOL) scale were used to evaluate patients' quality of life. Results Compared with the control group after the intervention, the serum TP [(76.53±9.79) g/L], [ALB (49.08±5.56) g/L], [HGB (126.56±18.17) g/L], [KPS (81.91±8.07) points] and QOL [(47.84±6.75) points] in the experimental group were significantly higher than those in the control group [(70.10±9.32) g/L, (45.79±5.70) g/L, (118.20±18.09) g/L, (75.46±8.32) points and (40.30±6.96) points, t=3.207, 2.795, 2.203, 3.765 and 5.262, all P < 0.05]. Compared with the control group after the intervention, ALT [(42.68±9.71) U/L] and AST [(43.29±9.48) U/L] in the experimental group were significantly lower than those in the control group [(47.15±9.20) U/L and (49.03±9.42) U/L; t=2.253, 2.901, all P < 0.05]. Conclusion Ultrasonic pulsed conductance therapy combined with auricular point pressing with beans can significantly improve the nutritional status and liver function of patients with liver cancer undergoing arterial perfusion chemotherapy, which also can improve the quality of life of patients.
- Liver cancer /
- Ultrasonic pulsed conductance /
- Auricular point pressing with beans /
- Quality of life /
- Liver function

HTML全文

表 1 2组肝癌动脉灌注化疗患者干预前后营养状况指标比较(x ±s, g/L)

Table 1. Comparison of nutritional status indicators between two groups of patients with liver cancer receiving arterial infusion chemotherapy before and after intervention (x ±s, g/L)

组别	例数	TP		ALB		HGB
组别	例数	干预前	干预后	干预前	干预后	干预前	干预后
观察组	50	65.29±9.61	76.53±9.79^a	40.24±5.63	49.08±5.56^a	110.23±17.08	126.56±18.17^a
对照组	42	64.73±9.80	70.10±9.32^a	39.95±5.75	45.79±5.70^a	109.67±16.94	118.20±18.09^a
t值		0.276	3.207	0.244	2.795	0.157	2.203
P值		0.783	0.002	0.808	0.006	0.875	0.030
注：与干预前比较，^aP＜0.05。

下载: 导出CSV

表 2 2组肝癌动脉灌注化疗患者干预前后肝功能指标比较(x ±s, U/L)

Table 2. Comparison of liver function indexes between two groups of patients with hepatocellular carcinoma receiving arterial infusion chemotherapy before and after intervention (x ±s, U/L)

组别	例数	ALT		AST
组别	例数	干预前	干预后	干预前	干预后
观察组	50	85.27±9.65	42.68±9.71^a	90.28±10.35	43.29±9.48^a
对照组	42	84.84±9.19	47.15±9.20^a	89.51±10.37	49.03±9.42^a
t值		0.218	2.253	0.355	2.901
P值		0.828	0.027	0.723	0.005
注：与干预前比较，^aP＜0.05。

下载: 导出CSV

表 3 2组肝癌动脉灌注化疗患者干预前后生活质量评分比较(x ±s, 分)

Table 3. Comparison of quality of life scores between two groups of patients with hepatocellular carcinoma receiving arterial infusion chemotherapy before and after intervention (x ±s, points)

组别	例数	KPS评分		QOL评分
组别	例数	干预前	干预后	干预前	干预后
观察组	50	72.35±8.25	81.91±8.07^a	35.38±6.04	47.84±6.75^a
对照组	42	70.04±8.13	75.46±8.32^a	34.93±6.20	40.30±6.96^a
t值		1.347	3.765	0.352	5.262
P值		0.181	< 0.001	0.726	< 0.001
注：与干预前比较，^aP＜0.05。

下载: 导出CSV

参考文献(20)

[1]	SIA D, VILLANUEVA A, FRIEDMAN S L, et al. Liver cancer cell of origin, molecular class, and effects on patient prognosis[J]. Gastroenterology, 2017, 152(4): 745-761. doi: 10.1053/j.gastro.2016.11.048
[2]	GAO Y X, YANG T W, YIN J M, et al. Progress and prospects of biomarkers in primary liver cancer (Review)[J]. Int J Oncol, 2020, 57(1): 54-66.
[3]	THIELS C A, D'ANGELICA M I. Hepatic artery infusion pumps[J]. J Surg Oncol, 2020, 122(1): 70-77. doi: 10.1002/jso.25913
[4]	KONDO Y, FUKUDA R. Cutting edge of hepatic artery infusion chemotherapy for hepatocellular carcinoma[J]. Gan To Kagaku Ryoho, 2020, 47(1): 1-5.
[5]	贾文霞, 赵红兵, 陈桂杰, 等. 肝癌的中医用药方法[J]. 中国中医基础医学杂志, 2017, 23(1): 121-123. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYJC201701050.htm JIA W X, ZHAO H B, CHEN G J, et al. Using drug thinking of traditional chinese medicine on liver cancer[J]. Chinese Journal of Basic Medicine in Traditional Chinese Medicine, 2017, 23(1): 121-123. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYJC201701050.htm
[6]	刘柳, 程秋骆, 白长川, 等. 中医药防治肝癌复发转移的研究进展[J]. 临床肝胆病杂志, 2021, 37(5): 1216-1220. doi: 10.3969/j.issn.1001-5256.2021.05.051 LIU L, CHENG Q L, BAI C C, et al. Advances of traditional Chinese medicine in prevention and treatment of recurrence and metastasis of liver cancer[J]. Journal of Clinical Hepatology, 2021, 37(5): 1216-1220. doi: 10.3969/j.issn.1001-5256.2021.05.051
[7]	中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗规范(2019年版)[J]. 临床肝胆病杂志, 2020, 36(2): 277-292. doi: 10.3969/j.issn.1001-5256.2020.02.007 Medical Administration Bureau of the National Health Commission of the People's Republic of China. Guidelines for diagnosis and treatment of primary liver cancer in China (2019 edition)[J]. Journal of Clinical Hepatology, 2020, 36(2): 277-292. doi: 10.3969/j.issn.1001-5256.2020.02.007
[8]	CLANCEY J K. Karnofsky performance scale[J]. J Neurosci Nurs, 1995, 27(4): 220.
[9]	祝葆华, 万崇华, 王坤, 等. FLIC、SF-36和QOL-LC量表在肝癌患者生活质量测定中的应用比较[J]. 中国循证医学杂志, 2012, 12(10): 1175-1179. https://www.cnki.com.cn/Article/CJFDTOTAL-ZZXZ201210006.htm ZHU B H, WAN C H, WANG K, et al. Comparisons among FLIC, SF-36 and QOL-LC in measuring quality of life of patients with liver cancer[J]. Chinese Journal of Evidence-Based Medicine, 2012, 12(10): 1175-1179. https://www.cnki.com.cn/Article/CJFDTOTAL-ZZXZ201210006.htm
[10]	BROUTIER L, MASTROGIOVANNI G, VERSTEGEN M M, et al. Human primary liver cancer-derived organoid cultures for disease modeling and drug screening[J]. Nat Med, 2017, 23(12): 1424-1435.
[11]	马颖, 马明, 张朝霞, 等. 血清恶性肿瘤特异性生长因子对原发性肝癌介入治疗的疗效评估价值[J]. 中华全科医学, 2018, 16(3): 343-345. doi: 10.16766/j.cnki.issn.1674-4152.000095 MA Y, MA M, ZHANG C X, et al. The efficacy prediction diagnostic value of tumor specific growth factor for primary hepatic carcinoma patients received transcatheter arterial chemoembolization[J]. Chinese Journal of General Practice, 2018, 16(3): 343-345. doi: 10.16766/j.cnki.issn.1674-4152.000095
[12]	UESHIMA K, OGASAWARA S, IKEDA M, et al. Hepatic arterial infusion chemotherapy versus sorafenib in patients with advanced hepatocellular carcinoma[J]. Liver Cancer, 2020, 9(5): 583-595.
[13]	LIU M, SHI J, MOU T, et al. Systematic review of hepaticarterial infusion chemotherapy versus sorafenib in patients with hepatocellular carcinoma with portal vein tumor thrombosis[J]. J Gastroenterol Hepatol, 2020, 35(8): 1277-1287.
[14]	刘欣源, 李敬华, 王映辉, 等. 基于社团分析对中医辨治原发性肝癌经验的讨论[J]. 世界科学技术-中医药现代化, 2020, 22(12): 4360-4366. https://www.cnki.com.cn/Article/CJFDTOTAL-SJKX202012040.htm LIU X Y, LI J H, WANG Y H, et al. Discussion on the experience of traditional Chinese medicine in treating primary liver cancer based on community analysis[J]. World Science and Technology-Modernization of Traditional Chinese, 2020, 22(12): 4360-4366. https://www.cnki.com.cn/Article/CJFDTOTAL-SJKX202012040.htm
[15]	叶杨, 曹谨茹, 郑文浩. 超声脉冲电导联合康复锻炼对全膝关节置换围手术期的影响[J]. 新中医, 2019, 51(8): 291-294. https://www.cnki.com.cn/Article/CJFDTOTAL-REND201908051.htm YE Y, CAO J R, ZHENG W H. A study on effect of ultrasonic pulse conductance combined with rehabilitation exercises on total knee arthroplasty during perioperative period[J]. Journal of New Chinese Medicine, 2019, 51(8): 291-294. https://www.cnki.com.cn/Article/CJFDTOTAL-REND201908051.htm
[16]	费敏, 王莉, 张明洁, 等. 五行音乐疗法结合耳穴埋豆在缓解ICU患者的焦虑、抑郁情绪中的应用[J]. 解放军护理杂志, 2017, 34(15): 34-36. https://www.cnki.com.cn/Article/CJFDTOTAL-JFHL201715009.htm FEI M, WANG L, ZHANG M J, et al. Application of five elements music therapy combined chinese auriculotherapy in relieving anxiety and depression in ICU patients[J]. Nursing Journal of Chinese People's Liberation Army, 2017, 34(15): 34-36. https://www.cnki.com.cn/Article/CJFDTOTAL-JFHL201715009.htm
[17]	宋慧锋, 詹江红, 刘泽萍, 等. 耳穴埋豆治疗不同中医证型维持性血液透析失眠临床研究[J]. 新中医, 2019, 51(12): 289-291. https://www.cnki.com.cn/Article/CJFDTOTAL-REND201912090.htm SONG H F, ZHAN J H, LIU Z P, et al. Clinical study on method of auricular point pressing with beans for patients undergoing maintenance hemodialysis with insomnia of different chinese medicine syndrome types[J]. Journal of New Chinese Medicine, 2019, 51(12): 289-291. https://www.cnki.com.cn/Article/CJFDTOTAL-REND201912090.htm
[18]	DATTA J, NARAYAN R R, KEMENY N E, et al. Role of hepatic arteryinfusion chemotherapy in treatment of initially unresectable colorectal livermetastases: A review[J]. JAMA Surg, 2019, 154(8): 768-776.
[19]	马明, 马颖, 孟塬, 等. 外周血炎症指标对肝动脉介入化疗栓塞术后感染的预测诊断价值分析[J]. 中华全科医学, 2018, 16(4): 549-551. doi: 10.16766/j.cnki.issn.1674-4152.000151 MA M, MA Y, MENG Y, et al. Predictive diagnosis value of peripheral blood inflammation index for infection after transcatheter arterial chemoembolization[J]. Chinese Journal of General Practice, 2018, 16(4): 549-551. doi: 10.16766/j.cnki.issn.1674-4152.000151
[20]	IMAMINE R, SHIBATA T, SHINOZUKA K, et al. Complications in hepaticarterial infusion chemotherapy: Retrospective comparison of catheter tipplacement in the right/left hepatic artery vs. the gastroduodenal artery[J]. Surg Today, 2017, 47(7): 851-858.